{"log_id": 7583920751280715439, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 8e-06, "average": 0.999111, "min": 0.982486}, "location": {"width": 822, "top": 156, "height": 49, "left": 238}, "words": "必须预防潜伏性结核感染。有些治疗前潜伏性结核感染检测为阴性的患者,使用"}, {"probability": {"variance": 3.1e-05, "average": 0.998299, "min": 0.966577}, "location": {"width": 822, "top": 202, "height": 52, "left": 236}, "words": "本品后发展为活动性结核感染。使用本品过程中医生应监测患者有活动性结核感"}, {"probability": {"variance": 8e-06, "average": 0.998843, "min": 0.983285}, "location": {"width": 823, "top": 252, "height": 51, "left": 233}, "words": "染的体征和症状,包括那些潜伏性感染检测阴性的患者。并应参考适用的当地治"}, {"probability": {"variance": 6e-06, "average": 0.998931, "min": 0.985924}, "location": {"width": 824, "top": 301, "height": 50, "left": 232}, "words": "疗指南。如果患者确诊为潜伏性结核病,则在开始使用本品前必须按照当地推荐"}, {"probability": {"variance": 0.000122, "average": 0.997009, "min": 0.933397}, "location": {"width": 821, "top": 349, "height": 51, "left": 231}, "words": "的方法进行抗结核治疗。在这种情况下,应慎重考虑使用本品治疗的受益/风险"}, {"probability": {"variance": 1e-06, "average": 0.999237, "min": 0.995586}, "location": {"width": 502, "top": 396, "height": 45, "left": 228}, "words": "平衡。类风湿关节炎患者结核感染的几率会更高"}, {"probability": {"variance": 1.4e-05, "average": 0.998378, "min": 0.979522}, "location": {"width": 778, "top": 447, "height": 49, "left": 274}, "words": "应告知患者在使用本品治疗期间或治疗以后,患者若出现结核病(例如,持"}, {"probability": {"variance": 0.006382, "average": 0.983166, "min": 0.57594}, "location": {"width": 629, "top": 494, "height": 45, "left": 224}, "words": "续性咳嗽、体重减轻和低热)的体征/症状均应寻求医学指导"}, {"probability": {"variance": 1.2e-05, "average": 0.998171, "min": 0.9892}, "location": {"width": 195, "top": 540, "height": 36, "left": 224}, "words": "乙型肝炎病毒激活"}, {"probability": {"variance": 2.5e-05, "average": 0.997917, "min": 0.974777}, "location": {"width": 778, "top": 585, "height": 58, "left": 267}, "words": "曾有慢性乙型肝炎病毒的携带者接受包括本品在内的抑制剂治疗时出"}, {"probability": {"variance": 0.003657, "average": 0.974547, "min": 0.719781}, "location": {"width": 810, "top": 638, "height": 48, "left": 220}, "words": "现乙肝病毒(HBV)激活的报告。有HBV感染风险的患考在开始抗TNF治疗前"}, {"probability": {"variance": 0.004766, "average": 0.981091, "min": 0.713775}, "location": {"width": 362, "top": 684, "height": 40, "left": 219}, "words": "必须对先前HBV感染情况进行评价"}, {"probability": {"variance": 0.002189, "average": 0.986625, "min": 0.799732}, "location": {"width": 392, "top": 733, "height": 39, "left": 265}, "words": "尚不明确本品和HBV激活的因果关系"}, {"probability": {"variance": 0.000295, "average": 0.992245, "min": 0.935159}, "location": {"width": 288, "top": 745, "height": 33, "left": 750}, "words": "为HBV携带者的患者使用本"}, {"probability": {"variance": 0.007063, "average": 0.981869, "min": 0.494001}, "location": {"width": 824, "top": 774, "height": 60, "left": 215}, "words": "品时,应谨慎使用。如果HBV携带者使用本治疗,应监测HBV感染激活的体"}, {"probability": {"variance": 2e-06, "average": 0.999095, "min": 0.994688}, "location": {"width": 388, "top": 826, "height": 40, "left": 211}, "words": "征和症状,必要时应采取恰当的治疗"}, {"probability": {"variance": 0, "average": 0.999621, "min": 0.998938}, "location": {"width": 147, "top": 875, "height": 30, "left": 211}, "words": "丙型肝炎恶化"}, {"probability": {"variance": 0, "average": 0.996599, "min": 0.996599}, "location": {"width": 77, "top": 858, "height": 77, "left": 943}, "words": "★"}, {"probability": {"variance": 0.004075, "average": 0.980335, "min": 0.645538}, "location": {"width": 830, "top": 917, "height": 60, "left": 253}, "words": "曾有使用本品治疗的患者出丙型肝炎恶化的报告,但是尚不明确本品和丙"}, {"probability": {"variance": 1.6e-05, "average": 0.99824, "min": 0.986431}, "location": {"width": 245, "top": 969, "height": 36, "left": 209}, "words": "型肝炎恶化的因果关系"}, {"probability": {"variance": 0.032229, "average": 0.924569, "min": 0.401429}, "location": {"width": 247, "top": 1014, "height": 42, "left": 206}, "words": "糖尿病患者的低血糖"}, {"probability": {"variance": 0.001514, "average": 0.989928, "min": 0.786503}, "location": {"width": 767, "top": 1065, "height": 51, "left": 254}, "words": "曾有患者使用糖尿病治疗药物后使用本品治疗出现低血糖症的报告,其中一"}, {"probability": {"variance": 6.1e-05, "average": 0.997292, "min": 0.967377}, "location": {"width": 414, "top": 1111, "height": 44, "left": 203}, "words": "些患者不得不减使用抗糖尿病的药物"}, {"probability": {"variance": 6e-06, "average": 0.998444, "min": 0.990701}, "location": {"width": 292, "top": 1160, "height": 38, "left": 203}, "words": "本品和阿那白滞素联合治疗"}, {"probability": {"variance": 8e-06, "average": 0.998618, "min": 0.984144}, "location": {"width": 774, "top": 1209, "height": 49, "left": 255}, "words": "与单独使用本品相比,本品和阿那白滞素联合治疗与严重感染和中性粒细胞"}, {"probability": {"variance": 1.2e-05, "average": 0.998317, "min": 0.984946}, "location": {"width": 826, "top": 1255, "height": 52, "left": 202}, "words": "减少风险增高相关。并未证实这种联合疗法可以增加临床效果。因此不推荐本品"}, {"probability": {"variance": 1e-06, "average": 0.999063, "min": 0.996577}, "location": {"width": 688, "top": 1304, "height": 46, "left": 199}, "words": "和阿那白滞素联合使用(参见“药物相互作用”和“不良反应”)"}, {"probability": {"variance": 2e-06, "average": 0.998647, "min": 0.995364}, "location": {"width": 270, "top": 1352, "height": 36, "left": 196}, "words": "本品和阿巴他塞联合治疗"}, {"probability": {"variance": 9e-06, "average": 0.99867, "min": 0.984546}, "location": {"width": 763, "top": 1401, "height": 47, "left": 245}, "words": "在临床研究中,本品和阿巴他塞联合治疗导致严重不良事件的发生率增加"}, {"probability": {"variance": 1e-06, "average": 0.99909, "min": 0.995566}, "location": {"width": 623, "top": 1446, "height": 48, "left": 195}, "words": "并未证实这种联合疗法可以增加临床效果,因此不推荐使用"}, {"probability": {"variance": 1e-06, "average": 0.999486, "min": 0.998215}, "location": {"width": 99, "top": 1497, "height": 30, "left": 195}, "words": "变态反应"}], "language": 3}